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The gut microbiome is the collection of all microbial cells and associated genetic material present
in the digestive tract of a host. Its composition depends on the gut environment and nutrition
provided by the host (1). In turn, the microbes help the host by metabolizing complex nutrients,
protecting against pathogens and priming their immune system (1, 2). In fact, the influence of
the gut microbiome on host development goes beyond nutrition and immune response, by also
regulating host behavioral and neurological responses (3, 4).
Microbiome-associated phenotypes can be seen as means for adaptation and natural selection,
presenting an accessible point on which selection could work to tweak host-phenotype in case of
changes in environmental conditions (5). From an animal perspective, the microbiome-associated
phenotypes gained interest when Bercik et al. showed that fecal matter transplantation could direct
strain-specific behavior of the recipient toward strain-specific behavior of the donor (6). Since then,
a growing body of evidence has supported the effects of the microbiome on brain and behavior and
the concept of a gut-microbiome-brain axis [see for reviews (3, 4)].
Although the microbiome-gut-brain-axis has been implicated in the pathophysiology of various
(mental) diseases (3, 4), it is often an overlooked aspect in many (metabolic) disorders associated
with behavioral deficits and treatments on a dietary basis. Which is remarkable, as diet is one of the
main determinants of the gut microbiome and affects the (development) of cognitive (dys)function
(7, 8). Moreover, beneficial effects of probiotic treatment on cognition have been reported for
pathological conditions such as irritable bowel syndrome and coeliac disease (9).
Despite the growing interest in gut microbiome, the ecological aspects associated with these
microbial communities are often not considered in the interpretation of the data, although they
might contribute to the great variability in host performance often observed after microbiome
manipulation, potentially leading to inconclusive interpretation of the data (10, 11). For instance,
as communities, the gut microbiome is not static, being subjected to large fluctuations that reflect
interactions among resident and transient microbial species and the host. From an ecological
perspective, these interactions are driven by rules associated with microbial succession, as they
reflect changes in community composition in response to processes such as selection and drift
(12). Moreover, approaches targeting microbiome manipulation, including the development of
probiotics (the “good” bacteria) or prebiotics (food for probiotics), require unraveling the ecological
principles controlling microbial invasion, where mechanisms associated with microbial diversity
and resource competition can help predicting the outcome of these strategies (11).
Despite the potential of using microbiome-related strategies to improve current treatment
and neurological outcome of (metabolic) disorders, we argue that unraveling the ecological
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principles associated with the community dynamics is crucial,
and subsequently a prerequisite to ensure the success in
microbial-based treatments. To put our opinion in context,
we will use the metabolic disorder phenylketonuria (PKU)
to illustrate and explain how general concepts of community
dynamics and resource availability, eco-evolutionary aspects and
microbial invasions, apply in situations where the environment
of the gastrointestinal tract is challenged and diet or probiotics
are used to prevent neurological problems.
THE GUT MICROBIOME IN THE CONTEXT
OF PKU
PKU is an enzymatic deficiency of the hepatic phenylalanine
hydroxylase which results in dramatically increased levels of
Phe (>600 µmol/L). It can reach levels that are considered to
be toxic for the brain, leading to severe intellectual disability
(13–15). The most common treatment is to restrict the intake
of natural protein in the diet, thus preventing high Phe
levels in the brain, while supplementing with amino acids and
essential micronutrients to avoid deficiencies (15–17). When
followed early and continuously, this treatment is very effective
in keeping Phe levels within an acceptable range (360–600
µmol/L), preventing severe high-Phe associated intellectual
disability (15). Nevertheless, in many PKU patients with normal
cognitive function Phe levels still influence brain performance
(18). Alternatively, it has been shown that inconsistencies in
neurocognitive, psychosocial and metabolic consequences of
PKU remain, despite treatment (19–22).
It has been shown, that elevated Phe levels are not only
present in the blood and brain, but are also manifesting
in the gut (23). The microbes in the gut environment are
constantly competing for resources, which become available
either through host nutrition or the by-products generated
by the microbial chemical food webs (24, 25). Together, the
selective pressure exerted by the available resources and biotic
interactions pressure play important roles in determining the
microbiome composition in the gut of a given host (12,
26, 27). This means that the microbiome of PKU patients
is constantly challenged by situations ranging between two
extremes, depending on adherence to treatment; untreated
with altered amino acid profiles and high Phe-levels, or low
Phe-levels accompanied by a change in resource availability
due to the strict dietary requirements. As the microbiome is
adaptive in nature, this is likely to result in an altered microbial
community. In both situations, alterations are likely to cause
a less diverse microbiome, as Phe has been shown to be
toxic to certain cell types (neurons), and resource restriction
(natural protein) will challenge microbial species that either
rely on these resources or are vulnerable to it, making it
less likely to establish or to be successful (survival). Results
from both PKU mice and patients show that, indeed, the
PKU-associated microbiome is often less diverse and more
variable between individuals, indicating dominance of a few
species within a community (28–31). Moreover, studies that have
examined prebiotic supplementation in PKU infant formula or
the prebiotic properties of medical foods (glycomacropeptide)
showed promising results in maintaining or increasing microbial
diversity, indicating that altered resources might influence
microbiome diversity in PKU (30, 32).
From a microbial ecology standpoint, the consequences of a
less diverse microbiome include the community susceptibility
to disturbances. Ecological theories predict that high diversity
acts a biotic barrier, contributing to a stable microbiome or
promoting microbiome resilience, capable of returning to the
original, healthy state, upon disturbance. Thus, a reduction in
gut microbial diversity significantly limits the ability of the
microbiome to withstand major shifts, potentially leading to
alternate, diseased, stable states (33, 34).
Another importance consequence of reduction in gut
microbiome diversity or shifts in composition in PKU patients
is the associated changes in the metabolite profiles of the
microbiome, potentially modulating the chemical food web,
thus influencing stability, as well as the molecules involved
in microbiome-gut-brain signaling and brain functioning (35–
38). In general, although many functions carried out by the
microbiome show functional redundancy, i.e., that multiple
populations are capable of carrying out that function, variability
in the observed function after microbiome manipulation is
greater than the change in gene frequency (10). This means
that the interactions within the community strongly impact
the functionality of the microbiome. As these functions
include production of neurological signaling molecules, a
dysfunctional microbiome could lead to behavioral symptoms.
In case of dietary treated pathological conditions like PKU,
the functionality of the microbiome could therefore impact the
neurocognitive, psychosocial and metabolic outcome, despite
a highly demanding diet. To optimize the outcome, and thus
improving quality of life, a promising alternative would be
the development of probiotics that could promote microbial
diversity and microbiome functionality. Such approaches have
been successfully used in other metabolic diseases (obesity
related insulin insensitivity and type 2 diabetes), which are also





Probiotic supplementation for PKU can serve two purposes—
it can be used to escape behavioral problems associated
with treated PKU and it can be utilized to lower absorption
of Phe from the gut by utilizing microbial metabolism.
Although it has been shown that colonization is not
necessary for probiotic action, interactions with the
commensal microbiota will make supplementation less
controllable and might lead to the unpredictable effects
(41). Colonization of a desired probiotic or microbial
consortia will therefore lead to longer lasting and more
reproducible effects. Thus, for successful probiotic
supplementation, general concepts such as community
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FIGURE 1 | A schematic overview of potential consequences of probiotic supplementation. (A) An altered resource availability due to dietary restriction. (B) When
presenting a probiotic (indicated by green microbes), these species will have to compete for available resources (represented by the blue color). (C) When the microbial
diversity is low, resource availability will be sufficient for successful establishment and growth of the desired probiotic. However, when the microbial diversity is high, it
usually correlates with high resource utilization and thus lower resource availability for the invading probiotic, leading to high competition and lack of establishment. This
increased competition can either lead to (D) (genetic) adaptation of either the probiotic or resident species and (E) permanent or transient changes in the composition
and functionality of the resident species, which in case of keystone species could lead to dramatic shifts in microbial community. These community dynamics could
therefore lead to unpredictable changes in microbiome composition and potentially different effects on brain functioning then initially predicted from in vitro studies.
dynamics, microbial invasions and colonization are important
to take into consideration to increase treatment effectiveness
and safety.
From an ecological perspective, probiotic supplementation
can be studied in the context of microbial invasions, where the
probiotic non-indigenous strain is introduced in large numbers
into an existing community [(11, 42); Figure 1]. For microbial
invasion to be successful, the invader has to overcome both
abiotic (i.e., environmental factors like pH and temperature)
and biotic resistance imposed by the resident community
(Figure 1B). Ecological theory predicts that effectiveness and
success of a probiotic treatment depends on the ability of
the probiotic strain to invade and colonize the gut—which is
correlated with their high growth rates, phenotypic plasticity
and genetic diversity—but also depends on its capacity to
compete for resources in the presence of the native gut
microbiome (11, 43, 44). It has been shown that the success
of invasion—in this case, the establishment of a probiotic
strain—is negatively correlated with microbiome diversity (11,
45, 46). Specifically, diverse microbial communities explore the
metabolic resources available in the gut in a more efficient
manner, thus limiting the number of niches available for
invaders (probiotic) to get established. On the other hand,
when food resources are not fully consumed and invading
species are capable of utilizing empty niches, the chances
of establishment and growth are high (Figure 1C). In PKU,
dietary restrictions and/or the influence of changes in amino
acid profiles are likely responsible for lower species diversity
due to altered resource availability, as opposed to liberalized
dietary restrictions (Figure 1A). Thus, from the PKU perspective,
the observed low gut microbiome diversity might increase the
chances of probiotic establishment, although the altered resource
availability intrinsic to PKU diet could prevent establishment
and survival of the desired probiotics. Additional strategies
that increase the probiotic’s competitive ability, such as the
use of prebiotics that stimulate the growth of the probiotic
strain, or high phenotypic plasticity that ensure quick adaptation,
might increase the chances of successful colonization therefore
improving treatment effectiveness.
Examining microbiome dynamics during colonization
(whether is it permanent or not) or whether the microbes
were prone to adapt (mutate) within the gut-environment is
important to determine safety of a given probiotic (47). In PKU,
recent scientific advances give rise to the use of genetically
modified probiotics to lower the absorption of Phe from the
gut by relying on microbial metabolism (47–50). However,
although they have shown to be stable as probiotics, little is
known about how these supplements affect the ecological and
evolutionary dynamics of commensal microbiota. Even with
successful and beneficial introduction of the probiotics, the
effects on the resident community, and subsequently behavior,
might be more unpredictable—an aspect that is inherent to
all microbial invasions (34, 51). Moreover, in situations in
which the invader needs to compete for available resources,
this increases the selective pressures and the propensity for
horizontal gene transfer, which could lead to adaptation of
either the probiotic or resident species (Figure 1D) (52–55).
In the context of genetically modified bacteria, as for instance
the Phe lowering probiotic, this could lead to integration of the
modification in other (commensal) species, risking unfavorable
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expression of the given genes. Additionally, recent developments
have shown that the probiotic properties of certain probiotic
strains might be attributed to genes that induce mutational
patterns that increase the risk of developing colorectal cancer
(56). Thus, a systematic search for naturally occurring gut
microbiome strains capable of degrading Phe might represent
a more sustainable solution toward personalized medicine,
where the evolutionary principles of the gut microbiome are
considered (57).
Lastly, ecological principles associated with community
dynamics might influence the outcome of microbiome
manipulations due to the intricate relationship among microbial
populations and their chemical food web (34, 51). Due to these
community dynamics and its effect on resource availability,
successful invasions can displace or shift resident taxa and alter
community function, affecting multiple connections within
the network (25, 58, 59). For instance, loss of a keystone
species, one that is responsible for many connections in
a chemical network, would make the community prone
to collapse or create dramatic shifts in composition and
function (Figure 1E). Microbiome alterations due to pre- or
probiotics can therefore lead to changes in bacterial (metabolite)
profile, resulting in different effects than predicted by in vitro
studies, and to large impacts on the functionality of the entire
microbiome. This could also explain why microbiota transfer
therapy shows promising results, whereas supplementation
of pre- and probiotics leads to variable results (60, 61).
Unraveling the dynamics on composition, functionality and
potential interactions within the gut microbiome are thus
crucial to developing successful microbial based treatments
and predicting its effects on microbiome functioning and
cognitive outcome.
CONCLUDING REMARKS
Microbial-based strategies for relieving neurological symptoms
in various disorders are currently being studied more extensively.
Nevertheless, additional research is needed to gain insight in
the evolutionary and ecological microbial community dynamics.
These dynamics play a critical role in the stability, composition
and functional diversity of our gut microbiota, and thus the
safety and success of probiotic treatment. Moreover, these
ecological principles might explain the discrepancies found
between animal and human studies, where results in the often
more complex (human) microbiota are less profound and do not
lead to the desired outcomes after microbiome manipulation (62,
63). Examining bacterial metabolite profiles resulting from the
microbiome could uncover the exact mechanisms by which the
gut microbiome influences the brain and hence many behavioral
domains. It then could be used to develop personalized probiotic
supplementation for disorders requiring dietary treatment,
including PKU.
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